David A. Siegel Galapagos Nv Transaction History

Two Sigma Advisers, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$52.3 - $71.59 $407,940 - $558,402	-7,800 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$51.32 - $68.5 $338,712 - $452,100	-6,600 Reduced 45.83%	7,800 $484,000
Q4 2021 Feb 14, 2022	SELL	$47.03 - $57.12 $32,921 - $39,984	-700 Reduced 4.64%	14,400 $794,000
Q3 2021 Nov 15, 2021	BUY	$52.17 - $70.2 $787,767 - $1.06 Million	15,100 New	15,100 $794,000

16.5M

77.1K

57.2K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.63B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.